News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,666 Results
Type
Article (14239)
Company Profile (281)
Press Release (253146)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79523)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50459)
Employer Resources (31)
FDA (5721)
Job Trends (5132)
News (144423)
Policy (10031)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21667)
ALS (63)
Alzheimer's disease (845)
Antibody-drug conjugate (ADC) (98)
Approvals (5746)
Artificial intelligence (122)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (51)
Brain cancer (20)
Breast cancer (150)
Cancer (1426)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (112)
Cell therapy (317)
Cervical cancer (8)
Clinical research (41038)
Collaboration (533)
Compensation (256)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (158)
Cystic fibrosis (76)
Data (1454)
Denatured (11)
Depression (29)
Diabetes (134)
Diagnostics (1297)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (89)
Earnings (29776)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48434)
Executive appointments (449)
FDA (6400)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (496)
Gene editing (93)
Generative AI (10)
Gene therapy (242)
GLP-1 (364)
Government (1078)
Grass and pollen (2)
Guidances (20)
Healthcare (6593)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (90)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (112)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (64)
Interviews (17)
IPO (7269)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (206)
Leadership (3)
Legal (1386)
Liver cancer (32)
Lung cancer (201)
Lymphoma (96)
Machine learning (3)
Management (7)
Manufacturing (136)
MASH (52)
Medical device (2597)
Medtech (2598)
Mergers & acquisitions (6281)
Metabolic disorders (383)
Multiple sclerosis (52)
NASH (13)
Neurodegenerative disease (64)
Neuropsychiatric disorders (25)
Neuroscience (1241)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1663)
Now hiring (22)
Obesity (192)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (54)
Parkinson's disease (119)
Partnered (8)
Patents (125)
Patient recruitment (73)
Peanut (35)
People (25614)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14493)
Phase II (19091)
Phase III (12069)
Pipeline (786)
Policy (44)
Postmarket research (852)
Preclinical (6095)
Press Release (30)
Prostate cancer (59)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (287)
Real estate (1418)
Recruiting (12)
Regulatory (8615)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (58)
Series A (98)
Series B (62)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1455)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1974)
State (1)
Stomach cancer (4)
Supply chain (22)
Tariffs (6)
The Weekly (36)
United States (12936)
Vaccines (211)
Venture capitalists (32)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Last 7 days (366)
Last 30 days (1362)
Last 365 days (19448)
2025 (5845)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17287)
Australia (2931)
California (3768)
Canada (1121)
China (345)
Colorado (145)
Connecticut (149)
Delaware (97)
Europe (37184)
Florida (455)
Georgia (115)
Idaho (16)
Illinois (226)
India (10)
Indiana (91)
Iowa (2)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (466)
Massachusetts (2984)
Michigan (70)
Minnesota (144)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (943)
New Mexico (12)
New York (1015)
North Carolina (543)
North Dakota (4)
Northern California (1663)
Ohio (111)
Oklahoma (9)
Oregon (21)
Pennsylvania (717)
Puerto Rico (5)
Rhode Island (18)
South America (208)
South Carolina (4)
Southern California (1455)
Tennessee (25)
Texas (436)
Utah (52)
Virginia (76)
Washington D.C. (30)
Washington State (345)
Wisconsin (14)
267,666 Results for "zucara therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial
Zucara Therapeutics Inc., today announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes (“T1D”) mellitus (“ZONE”).
September 25, 2023
·
3 min read
Drug Development
Zucara Therapeutics Announces Additional Funding from JDRF to Support ZT-01 Phase 2 Study
Zucara Therapeutics Inc. announced additional funding from JDRF, the leading global Type 1 diabetes research and advocacy organization.
June 15, 2023
·
4 min read
Drug Development
Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01
Zucara Therapeutics Inc., today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for ZT-01 for the prevention of night-time (nocturnal) hypoglycemia in patients with Type 1 Diabetes (“T1D”).
April 19, 2023
·
3 min read
Drug Development
Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01
Zucara Therapeutics Inc. today announced that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes (“T1D”).
June 22, 2022
·
3 min read
Drug Development
Zucara Therapeutics’ Positive Proof-of-Concept Data Secures Continued Funding Ahead of Planned Phase 2 Clinical Trial of ZT-01
Zucara Therapeutics Inc., today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.
September 19, 2022
·
4 min read
Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01
Zucara Therapeutics Inc. today announced that it has received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes (“T2D”).
May 2, 2022
·
3 min read
Drug Development
Zucara Reveals Hopeful Preclinical Data in Type 1 Diabetes
Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.
February 8, 2022
·
2 min read
·
Claudia Beezhold
Drug Development
Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes
Zucara Therapeutics Inc. today announced that the peer-reviewed journal, Diabetes, Obesity and Metabolism, has published a paper reporting positive preclinical data showing the effect and pharmacokinetics of ZT-01.
February 8, 2022
·
3 min read
Drug Development
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01.
July 28, 2021
·
2 min read
Drug Development
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01
Zucara Therapeutics Inc. a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01.
May 26, 2021
·
2 min read
1 of 26,767
Next
